A new trading day began on Friday, with Regenxbio Inc (NASDAQ: RGNX) stock price down -6.48% from the previous day of trading, before settling in for the closing price of $12.50. RGNX’s price has ranged from $10.49 to $28.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 72.63% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 24.86%. With a float of $44.51 million, this company’s outstanding shares have now reached $49.42 million.
In an organization with 344 employees, it is important to assess its efficiency.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.83%, while institutional ownership is 89.89%. The most recent insider transaction that took place on Sep 03 ’24, was worth 115,588. In this transaction Director of this company sold 10,000 shares at a rate of $11.56, taking the stock ownership to the 11,286 shares. Before that another transaction happened on Aug 01 ’24, when Company’s Director sold 10,100 for $13.51, making the entire transaction worth $136,454. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -1.41 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.86% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Here are Regenxbio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.27, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.8 million. That was better than the volume of 0.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 45.29%. Additionally, its Average True Range was 0.75.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 17.07%, which indicates a significant decrease from 25.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.26% in the past 14 days, which was higher than the 58.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.53, while its 200-day Moving Average is $15.64. However, in the short run, Regenxbio Inc’s stock first resistance to watch stands at $12.25. Second resistance stands at $12.82. The third major resistance level sits at $13.16. If the price goes on to break the first support level at $11.34, it is likely to go to the next support level at $11.00. The third support level lies at $10.43 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
With a market capitalization of 577.72 million, the company has a total of 49,256K Shares Outstanding. Currently, annual sales are 90,240 K while annual income is -263,490 K. The company’s previous quarter sales were 22,300 K while its latest quarter income was -52,990 K.
